Provectus Biopharmaceuticals Inc (PVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 73 | 417 | 470 | 490 | 614 |
| TOTAL | $278 | $568 | $650 | $977 | $760 |
| Non-Current Assets | |||||
| PPE Net | 4 | 4 | 4 | 5 | 5 |
| Other Non-Current Assets | 138 | 150 | 12 | 25 | 37 |
| TOTAL | $142 | $154 | $17 | $30 | $42 |
| Total Assets | $420 | $722 | $666 | $1,006 | $802 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,178 | 1,311 | 744 | 1,107 | 1,381 |
| Accrued Expenses | 142 | 148 | 152 | 173 | 134 |
| TOTAL | $6,472 | $6,493 | $5,735 | $6,976 | $6,225 |
| Non-Current Liabilities | |||||
| Long Term Debt | 24 | N/A | N/A | N/A | N/A |
| Deferred Revenues | 0 | 0 | 58 | 336 | 350 |
| Other Non-Current Liabilities | 104 | 142 | 0 | 0 | 0 |
| TOTAL | $115 | $104 | $N/A | $N/A | $N/A |
| Total Liabilities | $6,587 | $6,597 | $5,735 | $6,976 | $6,225 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 420,280 | 420,280 | 420,280 | 420,280 | 420,280 |
| Common Shares | 420 | 420 | 420 | 420 | 420 |
| Retained earnings | -261,689 | -260,378 | -258,563 | -257,423 | -255,056 |
| Other shareholders' equity | -62 | -50 | -12 | -57 | -46 |
| TOTAL | $-6,167 | $-5,875 | $-5,069 | $-5,969 | $-5,423 |
| Total Liabilities And Equity | $420 | $722 | $666 | $1,006 | $802 |